Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola J Curtin

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Biochemical Society Transactions|January 6, 2023
Targeting the DNA damage response for cancer therapyNicola J Curtin
Cancers|March 4, 2020
The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and SerendipityNicola J Curtin
Cell Cycle (Georgetown, Tex.)|December 9, 2014
PARP inhibitors target ATM+p53-defective gastric cancerNicola J Curtin
Nature Reviews. Cancer|November 24, 2012
DNA repair dysregulation from cancer driver to therapeutic targetNicola J Curtin
Expert Reviews in Molecular Medicine|April 20, 2005
PARP inhibitors for cancer therapyNicola J Curtin
Nature Reviews. Drug Discovery|September 5, 2020
Poly(ADP-ribose) polymerase inhibition: past, present and futureNicola J Curtin, Csaba Szabo
Current Opinion in Oncology|May 21, 2014
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcomaBritta Vormoor, Nicola J Curtin
Molecular Aspects of Medicine|February 2, 2013
Therapeutic applications of PARP inhibitors: anticancer therapy and beyondNicola J Curtin, Csaba Szabo
Expert Reviews in Molecular Medicine|September 28, 2019
Warburg and Krebs and related effects in cancerJudith E Unterlass, Nicola J Curtin
Methods in Molecular Biology (Clifton, N.J.)|July 12, 2017
Strategies Employed for the Development of PARP InhibitorsStacie Canan, Karen Maegley, Nicola J Curtin
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Biochemical Society Transactions|January 6, 2023
Targeting the DNA damage response for cancer therapyNicola J Curtin
Cancers|March 4, 2020
The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and SerendipityNicola J Curtin
Cell Cycle (Georgetown, Tex.)|December 9, 2014
PARP inhibitors target ATM+p53-defective gastric cancerNicola J Curtin
Nature Reviews. Cancer|November 24, 2012
DNA repair dysregulation from cancer driver to therapeutic targetNicola J Curtin
Expert Reviews in Molecular Medicine|April 20, 2005
PARP inhibitors for cancer therapyNicola J Curtin
Nature Reviews. Drug Discovery|September 5, 2020
Poly(ADP-ribose) polymerase inhibition: past, present and futureNicola J Curtin, Csaba Szabo
Current Opinion in Oncology|May 21, 2014
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcomaBritta Vormoor, Nicola J Curtin
Molecular Aspects of Medicine|February 2, 2013
Therapeutic applications of PARP inhibitors: anticancer therapy and beyondNicola J Curtin, Csaba Szabo
Expert Reviews in Molecular Medicine|September 28, 2019
Warburg and Krebs and related effects in cancerJudith E Unterlass, Nicola J Curtin
Methods in Molecular Biology (Clifton, N.J.)|July 12, 2017
Strategies Employed for the Development of PARP InhibitorsStacie Canan, Karen Maegley, Nicola J Curtin
Pageof 11